Status:
COMPLETED
The Impact of Mitotane Therapy on Serum Free Proteins in Patients With Adrenocortical Carcinoma
Lead Sponsor:
King's College Hospital NHS Trust
Conditions:
Adrenocortical Carcinoma
Eligibility:
All Genders
19-85 years
Brief Summary
This work will evaluate the effects of mitotane treatment on serum protein concentrations in patients treated for ACC with mitotane therapy and compare them to patients with an adrenal neoplasm and pr...
Detailed Description
Background: Adrenocortical Carcinoma (ACC) is a rare malignancy of the adrenal cortex. The annual incidence of ACC is thought to be between 0.5-2.0 cases per million. Adjunctive therapy with mitotane ...
Eligibility Criteria
Inclusion
- An individual being investigated for a malignant neoplasm treated with mitotane or matched number of patients with adrenal neoplasm not treated with mitotane under the Endocrinology team or a matched cohort of pregnant women.
- Patients included in the analysis were seen in the period between April of 2019 and June 2020 at King's College Hospital NHS Foundation Trust.
- \-
Exclusion
- Patients not investigated for a malignant neoplasm/ adrenal neoplasm under the Endocrinology team or were a matched cohort of pregnant women at King's College Hospital NHS Foundation Trust during the period Someone under the age of 18
Key Trial Info
Start Date :
April 11 2022
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
March 1 2023
Estimated Enrollment :
35 Patients enrolled
Trial Details
Trial ID
NCT05344027
Start Date
April 11 2022
End Date
March 1 2023
Last Update
March 8 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
King's College Hospital NHS Foundation Trust
London, United Kingdom, SE5 9RS